---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-25-000075"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2025-12-10T23:59:59+00:00"
generated_at: "2026-05-16T13:40:02.314259+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio Phase 1 AVALON trial of VTP-1000 shows safety, dose-dependent effect in celiac disease

## Summary
- VTP-1000 well-tolerated in SAD portion; no treatment-related serious adverse events.
- Dose-dependent pharmacological effect observed across 18 patients in three cohorts.
- MAD portion with gluten challenge ongoing; data expected in second half of 2026.
- VTP-1000 uses SNAP-TI platform to co-deliver gluten antigens and rapamycin, promoting immune tolerance.

## SEC filing metadata
- accession: 0001828185-25-000075
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2025-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000075/0001828185-25-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818525000075/brns-20251210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-25-000075
- JSON: https://secwatch.observer/filing/0001828185-25-000075.json
- Plain text: https://secwatch.observer/filing/0001828185-25-000075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.